Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01114165
Other study ID # UKM-SF-042010
Secondary ID
Status Completed
Phase Phase 4
First received April 23, 2010
Last updated December 4, 2012
Start date May 2010
Est. completion date September 2012

Study information

Verified date November 2012
Source University Hospital Muenster
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to assess the clinical value of the SeptiFast Test as an adjunct to traditional microbiological, clinical, and other laboratory assessments in early detection and identification of a potential pathogen and therefore early targeted antimicrobial management of neutropenic hematological patients with suspected infection or sepsis.


Description:

Infections, including sepsis, continue to be a major cause of morbidity and mortality in patients with hematologic diseases. Early diagnosis of infection, rapid identification of the causative pathogen(s), and prompt initiation of appropriate antimicrobial treatment (the first 24 hours are most critical) all have a major impact on mortality.

The LightCycler® SeptiFast Test MGRADE (SeptiFast Test) is an in vitro nucleic acid amplification test for the direct detection and identification of DNA from bacterial and fungal microorganisms in human EDTA whole blood. The SeptiFast test can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia. The test is used in conjunction with the patient's clinical presentation and established microbiological assays and other laboratory markers as an aid in antimicrobial treatment decision making for patients with suspected sepsis and other bloodstream infections.

This is a randomized prospective study of the use of the SeptiFast Test as an adjunct to traditional management of neutropenic haematological patients suspected of having infection or sepsis. The study will be performed in a two-armed manner. The blood sample for the SeptiFast Test will be collected from all included patients. However, analysis of the SeptiFast Test in the control group will only be performed at a later point in time; thus, in the control group results will not become available until the end of the study and, therefore, cannot be used for guiding clinical decisions.

Patients complete the study when the episode of infection or sepsis resolves, or the patient is discharged from a hospital, or the patient died.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient with hematological disease and neutropenia < 500/µl (or < 1000/µl, if criterion 5A is fulfilled)

2. Known or acute infection, or suspected infection, or sepsis, which clinically indicates investigation by blood culture

3. Time-frame after diagnosis or suspicion of infection or sepsis: < 72 hours

4. Species causing infection not known before inclusion

5. Patient fulfils criterion A or/and B

A. Indication for an initiation of antimicrobial therapy in patients with febrile neutropenia

- Neutropenia <500/µl or <1000/µl if decline to <500/µl is expected in the next 48h.

- Single (oral) temperature of = 38.3°C, or temperature = 38.0°C lasting for at least 1h or measured twice within 12h.

- No evidence of non-infectious cause of fever (blood products, drugs reactions, etc)

B. At least two of the following criteria:

- Temperature >38°C or <36°C

- Heart rate >90 beats/minute

- Respiratory rate >20 breaths/minute or PaCO2 <32 mmHg / 4,3 kPa

6. Patient is able to provide written informed consent

Exclusion Criteria:

1. Moribund patients with survival expectation < 24h

2. Younger than 18 years

3. Patient is not able to provide informed consent

4. Patients not suitable for study participation in the opinion of investigator

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Other:
Detection of microbial DNA in blood by SeptiFast Test
The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
Pathogen detection by blood culture
Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling

Locations

Country Name City State
Germany University Hospital Muenster Muenster North Rhine-Westphalia

Sponsors (3)

Lead Sponsor Collaborator
University Hospital Muenster Hoffmann-La Roche, Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of changes in empirical antimicrobial therapy up to the end of study participation No
Primary Time to the change to the targeted antimicrobial therapy at time point of change to the targeted antimicrobial therapy No
Secondary The number of patients with a potential pathogen identified by the SeptiFast Test, compared with the number of patients likely to have bloodstream infection or sepsis, as determined by a constructed clinical comparator at day 1 and 72h after study inclusion No
Secondary Number of patients having a change to a more appropriate antimicrobial (evaluated retrospectively by susceptibility) up to the end of study participation No
Secondary Time to identification of a potential pathogen at time point of identification of a potential pathogen No
Secondary Time to change antimicrobial to a more appropriate antimicrobial at time point of change to a more appropriate antimicrobial No
Secondary Duration (in days) of antimicrobials up to the end of study participation No
Secondary Change in condition severity (clinical parameters) daily No
Secondary Days in intensive care unit (ICU) at the end of study participation No
Secondary Ventilation duration in ICU (hours) at the end of study participation No
Secondary Days in hospital (from study inclusion) at the end of study participation No
Secondary All-cause death at the end of study participation No
Secondary Treatment costs up to the end of study participation No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3